Philadelphia, PA, July 17, 2008 – Both schizophrenia and bipolar disorder can be disabling conditions, and both present clinically with significant mood and psychotic symptoms. These two illnesses also share genetic variants that might be involved in the predisposition to both disorders. A new study scheduled for publication in the July 15th issue of Biological Psychiatry sought to analyze the patterns of gene expression in the brains of individuals diagnosed with one of these disorders to search for a common "characteristic [genetic] signature."
Using microarray gene expression, Drs. Ling Shao and Marquis Vawter tested whether there was a core set of genes shared in the predisposition or long term consequences of both illnesses. The researchers found 78 dysregulated genes, representing genes involved in nervous system development and cell death, which displayed differential expression compared to control subjects. As Dr. Vawter further explains, "the pattern of dysregulation was similar in the prefrontal cortex for both illnesses and pointed to key processes. Part of the set of core genes could be explained by medication responses; however most of these core genes did not appear to be correlated to medication response."
John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, adds: "The new findings by Drs. Shao and Vawter provide evidence that there are a large number of genes that show a similar pattern of abnormal regulation in their sample of post-mortem brain tissue from individuals who had been diagnosed with schizophrenia or bipolar disorder. This overlap could provide insight into the neurobiology of both disorders." Better understanding of the neurobiology related to the shared genes may offer a window into discovery of common brain mechanism(s) that could guide the identification of new and more effective treatments.
The authors also mention in their article recent discussions that have focused on considering schizophrenia and bipolar disorder as a single illness viewed along a continuum of mood and psychotic symptoms. Dr. Krystal concurs, noting that "we have traditionally treated these diagnoses as unrelated conditions even though many of the same medications, such as antipsychotic medications, are used to treat both conditions." Thus, there may be a need for our understanding of psychiatric diagnoses to evolve to fit the growing support of some common disease-related mechanisms that cross diagnostic boundaries, as evidenced by the findings in this study.
Notes to Editors:
The article is "Shared Gene Expression Alterations in Schizophrenia and Bipolar Disorder" by Ling Shao and Marquis P. Vawter. Drs. Shao and Vawter are affiliated with the Department of Psychiatry and Human Behavior, Functional Genomics Laboratory, School of Medicine, University of California, Irvine, California. The article appears in Biological Psychiatry, Volume 64, Issue 2 (July 15, 2008), published by Elsevier.
The authors' disclosures of financial and conflicts of interests are available in the article. Dr. Krystal's disclosures of financial and conflicts of interests are available at http://journals.elsevierhealth.com/webfiles/images/journals/bps/Biological_Psychiatry_Editorial_Disclosures_02_22_08.pdf.
Full text of the article mentioned above is available upon request. Contact Jayne M. Dawkins at (215) 239-3674 or ja.dawkins@elsevier.com to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length and Brief Reports of novel results, Commentaries, Case Studies of unusual significance, and Correspondence and Comments judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry (www.sobp.org/journal) is ranked 4th out of the 95 Psychiatry titles and 16th out of 199 Neurosciences titles on the 2006 ISI Journal Citations Reports® published by Thomson Scientific.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Journal
Biological Psychiatry